Drug Trial Radar · NCT00487630
Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease
Last checked: Nov 20, 2026Latest source record: Jun 18, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
34
Planned (sponsor's estimate)
Start
Jun 2005
Primary completion
Not stated
Study completion Jun 2009
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 18, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fabry disease (OMIM 301500) is an X-linked inborn error of sphingolipid metabolism resulting from the deficiency of the lysosomal enzyme alpha-galactosidase A. Heterozygous females for Fabry disease may be symptomatic with cardiac, renal or cerebrovascular involvement. Clearance of Gb3 and stabilization of renal function has been demonstrated in male patients treated with agalsidase beta (FABRAZYME). In contrast, no randomized, controlled study of the efficacy of recombinant alpha-galactosidase A has been reported in heterozygotes for Fabry disease.
Conditions
- Fabry Disease
Interventions
recombinant alpha-galactosidase ADrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Left ventricular massTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre de reference de la maladie de Fabry et des maladies hereditaires du tissu conjonctif. Assistance Publique - Hôpitaux de Paris
Paris, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.